Treatment Clinical Trials for Breast Neoplasm
Clinical trials are research studies that involve people. The clinical trials on this list are for breast neoplasm treatment. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
ErbB-2 Inhibitor ARRY-380, Palbociclib, and Letrozole in Treating Patients with Advanced or Metastatic Hormone Receptor and HER2 Positive Breast Cancer That Cannot Be Removed by Surgery
This phase Ib / II trial studies the side effects of ErbB-2 inhibitor ARRY-380, palbociclib, and letrozole and how well they work in treating patients with in hormone receptor and HER2 positive breast cancer that has spread to other places in the body and cannot be removed by surgery. ErbB-2 inhibitor ARRY-380, palbociclib, and letrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: University of Colorado Hospital, Aurora, Colorado
Viral Therapy In Treating Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of viral therapy in treating patients with squamous cell carcinoma of the head and neck that has returned (come back) after a period of improvement or has spread to other parts of the body or breast cancer that has spread to other parts of the body. A virus called encoding thyroidal sodium iodide symporter, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
Location: Mayo Clinic, Rochester, Minnesota
Chemotherapy with or without Metformin Hydrochloride in Treating Patients with HER2 Positive Breast Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well chemotherapy with or without metformin hydrochloride work in treating patients with HER2 positive breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, pertuzumab, and pegfilgrastim, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may prevent or lower risk of breast cancer and decrease cancer cells, lower risk of cancer spreading. It is not yet known whether giving metformin hydrochloride with chemotherapy will work better in treating patients with breast cancer.
Location: 6 locations
Trastuzumab, Pertuzumab, Tocilizumab in Treating Participants with Metastatic or Unresectable HER2 Positive Breast Cancer
This phase I trial studies the best dose and side effects of trastuzumab, pertuzumab and tocilizumab in treating participants with HER2 positive breast cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies such as trastuzumab, pertuzumab and tocilizumab, may interfere with the ability of tumor cells to grow and spread
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Breast Cancer Locator in Detecting the Location of Breast Cancer in Patients with Palpable Cancer
This clinical trial studies how well a breast cancer locator works in detecting the location of breast cancer in patients with cancer that can be felt by touch. Breast cancer locators may accurately localize breast cancer and may be a useful guide for surgeons to remove the cancer.
Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
18F-FBnTP Positron Emission Mammography in Detecting Breast Cancer in Patients with Intraductal Breast Cancer
This clinical trial studies how well 18F-FBnTP positron emission mammography works in detecting breast cancer in patients with intraductal breast cancer. 18F-FBnTP positron emission mammography may detect may detect breast lesions with better sensitivity and better specificity.
Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland
TPI 287 and Fractionated Stereotactic Radiation Therapy in Treating Patients with Brain Metastases from Breast or Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of TPI 287 when given together with fractionated stereotactic radiation therapy in treating patients with breast or non-small cell lung cancer that has spread to the brain. TPI 287 may help fractionated stereotactic radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Stereotactic radiation therapy delivers several small doses of radiation directly to the tumor over several days to kill and shrink tumors. Giving TPI 287 with fractionated stereotactic radiation therapy may kill more tumor cells.
Location: Moffitt Cancer Center, Tampa, Florida
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.
Location: See Clinical Trials.gov
BRCA1 Protein Expression in Patients With Metastatic Breast Cancer Receiving Pegylated Liposomal Doxorubicin Hydrochloride
This phase II trial studies breast cancer 1, early onset (BRCA1) protein expression in patients with metastatic breast cancer receiving pegylated liposomal doxorubicin hydrochloride. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Studying samples of tissue in the laboratory from patients receiving pegylated liposomal doxorubicin hydrochloride may help doctors learn more about the effects of BRCA1 protein expression. It may also help doctors understand how well patients respond to treatment.
Location: The University of Arizona Medical Center-University Campus, Tucson, Arizona
Ruxolitinib Phosphate in Treating Patients with Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well ruxolitinib phosphate works in treating patients with breast cancer that has spread from where it started to nearby tissue or to other places in the body and that cannot be removed by surgery. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 4 locations
Vaccine Therapy in Treating Patients with Stage IB-IIIA Breast Cancer
This pilot clinical trial studies the side effects of vaccine therapy in treating patients with stage IB-IIIA breast cancer. Vaccines made from peptides and immune stimulant may help the body build an effective immune response to kill tumor cells.
Location: See Clinical Trials.gov
Cabozantinib in Treating Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Involvement
This pilot phase II trial studies the side effects and how well cabozantinib-s-malate (cabozantinib) works alone and in combination with fulvestrant (pilot cohort) in treating patients with hormone receptor-positive breast cancer that has spread to the bone. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving cabozantinib-s-malate and fulvestrant together may be a better treatment for patients with hormone-receptor positive breast cancer.
Location: 5 locations
Letrozole Before Surgery in Treating Post-Menopausal Patients With Stage I-III Hormone-Sensitive Breast Cancer That Can Be Removed By Surgery
This clinical trial studies letrozole before surgery in treating post-menopausal patients with stage I-III hormone-sensitive breast cancer that can be removed by surgery. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery may reduce the amount of tissue that needs to be removed.
Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee
Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of buparlisib or alpelisib when given together with olaparib in treating patients with triple negative breast cancer or high grade serous ovarian cancer that has come back (recurrent). Buparlisib, alpelisib, and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: See Clinical Trials.gov